Filing Overview
Phathom Pharmaceuticals, Inc. filed this Form 8-K on May 24, 2024, reporting events occurring on May 23, 2024. The filing covers the 2024 Annual Meeting of Stockholders and amendments to the non-employee director compensation program. It does not provide quarterly or annual financial results.
Business Context and Reporting Period
Phathom Pharmaceuticals is a Delaware corporation whose common stock trades on Nasdaq under the symbol PHAT. The company is identified as an emerging growth company. The reported period is the May 23, 2024 annual meeting date and related board actions.
Financial and Operating Metrics
- The filing text does not provide revenue, net income or loss, cash flow, margins, debt, cash balances, liquidity measures, or other operating financial metrics.
- The filing does not provide financial guidance or a revised outlook.
- No material financial results or accounting developments are reported.
Material Changes and Corporate Actions
Annual Meeting Results
- Stockholders elected Michael F. Cola, Frank Karbe, and Asit Parikh, M.D., Ph.D. as Class II directors for three-year terms expiring at the 2027 annual meeting, subject to successor election and qualification.
- Votes for, withheld, and broker non-votes were respectively 24,131,545, 3,121,071, and 10,761,030 for Michael F. Cola; 25,007,043, 2,245,573, and 10,761,030 for Frank Karbe; and 21,332,226, 5,920,390, and 10,761,030 for Asit Parikh.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal 2024, with 37,887,951 votes for, 124,558 against, and 1,137 abstentions.
Director Compensation Program
- Effective May 23, 2024, the board amended the non-employee director compensation program.
- A newly elected non-employee director will receive an initial grant of 21,000 restricted stock units and options to purchase 35,000 common shares. One-third of the awards will vest on the first anniversary of the grant date, with the remainder vesting quarterly over the following 24 months, subject to continued board service.
- Each non-employee director will receive an annual grant of 10,500 restricted stock units and options to purchase 17,500 shares. These awards vest on the earlier of the first anniversary of the grant date or the next annual stockholders meeting, subject to continued service.
- Annual cash retainers for non-employee director and committee service were not changed.
- The company intends to file the amended compensation program as an exhibit to its Form 10-Q for the quarter ending June 30, 2024.
Guidance, Risks, Contingencies, and Unusual Items
- No management guidance, outlook, material risks, contingencies, litigation, or unusual financial items are disclosed in the filing.
- The increased equity awards may affect future share-based compensation expense and dilution, but the filing does not quantify either impact.
Key Facts for Investors to Verify
- Confirm the three Class II director elections and their terms through the company’s subsequent proxy or governance disclosures.
- Review the amended director compensation program when filed with the Form 10-Q for the quarter ending June 30, 2024.
- Assess the potential dilution and share-based compensation expense associated with the new restricted stock unit and option grants.
- Refer to the company’s periodic reports for cash, liquidity, debt, operating results, and forward-looking guidance, none of which is provided in this Form 8-K.